Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, was featured in the recent Mirum Pharmaceuticals announcement that the VISTAS Phase 2b study of volixibat met its primary endpoint in patients with primary sclerosing cholangitis (PSC) and cholestatic pruritus.
PSC is a rare, chronic liver disease with significant symptom burden and no approved therapies. In the VISTAS study, volixibat, an investigational oral IBAT inhibitor, demonstrated clinically meaningful reductions in cholestatic pruritus compared with placebo.
Congratulations to Mirum, the investigators, research teams (including Dr. Kowdley’s team in Seattle!), and participants who contributed to this important study.
